#1#2BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our preliminary fourth quarter and fiscal year ended December 31, 2022 operational and financial performance, including our revenue growth, non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate; ROIC; EBITDA; management's expectations for future financial and operational performance, expected growth, and business outlook; statements regarding our business focus, expected market growth and market size; and product performance. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions, the impact of any supply chain disruptions, continued volatility in the capital markets, the impact of Project Accelerate, the performance of breakout opportunities, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, fluctuations in foreign currency exchange rates and their impact, our ability to successfully implement our restructuring initiatives and other cost reduction initiatives, changing technologies, product development and market demand and acceptance of our products, the success of our R&D investment initiatives, the cost and pricing of our products, manufacturing, competition, loss of key personnel, dependence on collaborative partners, key suppliers and contract manufacturers, capital expenditures, debt levels, payment of dividends, government funding policies, changes in governmental regulations, the use and protection of intellectual property rights, litigation, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2021, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law. 2023 Bruker BRUKER 2023 JP Morgan Healthcare Conference | January 9, 2023 T 2#3YTD Q3 2022 FINANCIALS AND FY2023 YTD Q3 2022: Robust Organic Growth with Solid Margin Expansion Solid Q4 2022 Organic Revenue Growth, Strong 2023 Outlook YTD Q3 2022 Financials (all year-over-year) Revenue increased $87.9M, up +5.1% Organic revenue growth +10.7% (BSI +9.9%, BEST +18.7%); acquisitions tailwind +1.3%, FX headwind -6.9% * Non-GAAP gross margin 52.6%, up +160 bps * Non-GAAP operating margin 19.6%, up +80 bps Continuing significant investments in PA 2.0 R&D, M&S opex Non-GAAP EPS of $1.60, up 6% Revenues [$M] 1,822.3 2023 Bruker 1,734.4 YTD Q3-21 YTD Q3-22 Non-GAAP EPS $1.51 $1.60 - E I I Q4 2022 Preliminary Revenue Estimate and FY 2023 Outlook(1) Q4-22 preliminary revenue estimate: mid-to-high single digit % organic growth YoY2; reported revenue above consensus → Solid demand, with Q4-22 BSI book-to-bill expected at >1 → BSI backlog remains high due to supply chain constraints Preliminary 2023 outlook: mid-to-high single digit % organic revenue growth YoY Project Accelerate 2.0 initiatives performing well, Proteomics and Spatial Biology accelerating organically and inorganically BSI Geographic Mix (YTD 3Q 2022 revenue) YTD Q3-22 YTD Q3-21 (1) Please see disclosures on slide 21 (2) Q4-22 preliminary: GAAP revenue up low single digits % YoY: organic revenue up mid-to-high single digit %, ~7% headwind from FX, ~1.5% tailwind from acquisitions. 32% 33% { 31% BRUKER ROW: 4% 2023 JP Morgan Healthcare Conference | January 9, 2023 I#4#5PROTEOMICS AND MULTIOMICS Proprietary Tims TOF® Mass Spec Platform Enables 4D Proteomics™ Revolution Global timsTOF installed base end of 2022 at >600 units 2023 Bruker Single Cell Tissue Plasma Main classes of mentrane lipids fingulis Senes Tw 4D-Multiomics Sp 4D-Lipidomics 4D-Metabolomics 4D-Glycomics 4D-Proteomics 4D-Epiproteomics timsTOF Pro 2 Ultimate Workhorse timsTOF SCP Ultimate Sensitivity BRUKER timsTOF HT Ultimate Workhorse Extended Range timsTOF flex Ultimate Flexibility 2023 JP Morgan Healthcare Conference | January 9, 2023 1 LO 5#6#7BREAKOUT OPPORTUNITY 4D PROTEOMICS Research Highlight #2: timsTOF in large-scale plasma proteomics study of COVID-19 ▪ Drs. Hanno and Judith Steen at Children's Hospital, Boston, utilized the timsTOF Pro for plasma proteomics on 4,570 samples from 1,000 patients Resulting in most complete plasma proteome library to date Novel sample-preparation and bioinformatic workflows Combined with leading capabilities of timsTOF with dia-PASEF, can now be applied to future, large-scale plasma proteomics studies 7 - ■ 2023 Bruker 20 BRUKER TOF Pro BRUKER Professors Hanno and Judith Steen "The TIMSTOF platform was critical to our lab completing a demanding study of thousands of samples in plasma, something that until now was unachievable by MS methods. Now we actively look for larger sample cohorts because we know we have the capabilities." Dr. Hanno Steen, Associate Professor of Pathology, Harvard Medical School and PI, Children's Hospital 2023 JP Morgan Healthcare Conference | January 9, 2023 I 7#8BREAKOUT OPPORTUNITY 4D PROTEOMICS Research Highlight #3: timsTOF enabling higher throughput single-cell proteomics ■ - timsTOF SCP (Single Cell Proteomics) has a robust workflow and very high sensitivity, with >3,500 proteins identified on average in single cells ▪ Professor Nikolai Slavov at Northeastern University is pioneering plexDIA to combine sensitivity of Data Independent Analysis (DIA) with throughput of labeling to quantify > 1,000 protein groups per cell with only 5 min nanoLC gradients on timsTOF SCP 2023 Bruker Prof. Nikolai Slavov plexDIA: Multiplicative scaling 11-plex DIA 3-plexDIA LF-DIA 18-plex DDA Throughput # Parallel peptides # Parallel samples a MS1 MS2, dia-PASEF timsTOF SCP lon mobility Duty cycle time m/z range b Precursors per cell 4000 3000 2000 1000 0 Melanoma PDAC U-937 C 1250 Protein groups per cell 1000 750 500 250 d 30 8 Retention time (min) 0 timsTOF SCP timsTOF 0 500 Mean precursors/minute 1000 BRUKER e Protein Jaccard index 1.00 0.75 0.50 0.25 0.00 Within a run Across runs 2023 JP Morgan Healthcare Conference | January 9, 2023 18#9#10#11#12#13#14#15#16#17#18#19#20#21#22#23#24#25#26